UID:
(DE-602)gbv_165191303X
Format:
Online-Ressource (IX, 483 p. 19 illus., 16 illus. in color, digital)
ISBN:
9781461447320
Series Statement:
SpringerLink
Content:
This work will provide a historical perspective on tumor immunotherapy, discuss fundamental mechanisms of failed tumor rejection, look at passive strategies to boost anti-tumor immunity, as well as have an in-depth look at active strategies to boost anti-tumor immunity.
Content:
This volume is a comprehensive discussion of the major factors affecting tumor immunology and a discussion of all major anti-cancer immunotherapeutic agents approved by the Food and Drug Administration of the United States and by European agencies. Many promising but unapproved agents in clinical trials are also discussed, as are key pre-clinical developments. The major challenges and intellectual issues facing investigators developing novel immunotherapeutics are discussed in detail as are conceptual developments influencing current and future treatment strategies.Each chapter begins by defining all relevant key terms and concepts and provides pertinent background information so that the text will be accessible to newcomers to the field as well as to the expert. This text book should provide an excellent reference resource for investigators in tumor immunology, life sciences students, drug developers designing novel anti-cancer immunotherapeutics, and to other individuals with some scientific training wishing to gain a better understanding of the field of tumor immunotherapy.Although the field is evolving rapidly, we have taken pains to ensure that information was as up to date as possible as the text went to press.
Note:
Description based upon print version of record
,
Cancer Immunotherapy; Contents; Introduction; Part I: Overview; Chapter 1: Historical Perspectives and Current Trends in Cancer Immunotherapy; 1.1 Historical Perspective; 1.1.1 The History of Immunology Is Rooted in the History of Understanding Resistance to Infections; 1.1.2 Investigations in Infectious Disease Greatly Influenced Work in Tumor Immunology; 1.2 The Older Paradigm; 1.3 Shortcomings of the Older Paradigm; 1.4 Examples of the Too Much of a Bad Thing Paradigm in Ovarian Cancer; 1.5 Immunoediting: Another Formidable Hurdle to Successful Tumor Immunotherapy
,
1.6 Resistance to Immune Rejection Is a Fundamental Hallmark of Cancers1.7 Novel Clinical Approaches Based on the Newer Paradigm; 1.8 Challenges in Developing Newer Tumor Immunotherapies; 1.9 Conclusions and Summary; References; Chapter 2: T Cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment; 2.1 Cytotoxic T Lymphocytes; 2.2 T-Helper-1 Th1; 2.3 Th2; 2.4 Th17; 2.5 Treg; 2.6 Myeloid Dendritic Cells; 2.7 Macrophages; 2.8 Plasmacytoid Dendritic Cells; 2.9 B Cells; 2.10 Conclusions; References; Part II: Passive Strategies to Boost Antitumor Immunity
,
Chapter 3: Adoptive T Cell Transfer3.1 Introduction; 3.2 EBV-Associated Malignancies; 3.2.1 EBV-Associated Posttransplant Lymphoproliferative Disorder; 3.2.2 EBV-Specific CTL for Prophylaxis and Treatment of EBV-Associated Posttransplant Lymphoproliferative Disease; 3.2.3 EBV-Associated Lymphoma and Nasopharyngeal Carcinoma; 3.2.4 Improving EBV-Specific CTL Therapy for EBV-Related Lymphoma and Nasopharyngeal Carcinoma; 3.2.5 Summary of EBV-Associated Malignancies; 3.3 Tumor-Infiltrating Lymphocytes; 3.3.1 Generating TILs for Adoptive T Cell Transfer of Metastatic Melanoma Patients
,
3.3.2 Improving TIL Therapy: Modified Culture and Increased Lymphodepletion3.3.3 TIL Therapy for Ovarian Cancer; 3.3.4 Summary of TIL Studies; 3.4 Genetically Modified T Cells; 3.4.1 T Cell Receptor Transfer; 3.4.2 Adoptive T Cell Transfer for Metastatic Melanoma Using TCR Transfer; 3.4.3 Chimeric Antigen Receptors; 3.4.4 Costimulatory Domains to Improve CAR Function; 3.4.5 Expressing CARs on Virus-Specific CTL; 3.4.6 Overcoming Tumor Immune Evasion Strategies; 3.4.7 Summary of TCR Transfer and CARs; 3.5 Adoptive Therapy Using Natural Killer Cells
,
3.5.1 Adoptive Transfer of Allogeneic NK Cells3.5.2 Hurdles in the Use of NK Cells for Immunotherapy; 3.5.3 Summary on NK Cell Transfers; 3.6 Conclusions; References; Chapter 4: Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts; 4.1 Introduction; 4.1.1 Dendritic Cell Immunobiology; 4.1.2 Dendritic Cell Subsets; 4.1.2.1 Plasmacytoid Dendritic Cells; 4.1.2.2 Myeloid Dendritic Cells; 4.1.2.3 Ex Vivo-Generated Dendritic Cells; 4.2 Dendritic Cell Maturation; 4.2.1 Tolerogenic Dendritic Cells; 4.2.2 Cytokine Maturation Cocktails; 4.2.3 Maturation via Toll-Like Receptors
,
4.3 Dendritic Cell Antigen Loading
,
Introduction -- Historical Perspectives and Current Trends in Cancer Immunotherapy -- T cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment -- Adoptive T Cell Transfer -- Dendritic Cell-Based Cancer Immunotherapy: Achievements and novel concepts -- Peptide and Protein-based Cancer Vaccines -- Antigen Targeting to Dendritic Cells for Cancer Immunotherapy -- Cytokines in the Treatment of Cancer -- Immune Co-signaling to Treat Cance -- Managing Regulatory T cells -- Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and therapeutic perspectives -- Antibodies as Cancer Immunotherapy -- Targeted Toxins in Cancer Immunotherapy -- Miscellaneous Approaches and Considerations: TLR agonists and other inflammatory agents, anti-chemokine agents, infectious agents, tumor stroma targeting, age and sex effects, and miscellaneous small molecules -- Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies -- Monitoring Antigen-Specific Responses in Clinical Trials of Immunotherapy -- Index.
Additional Edition:
ISBN 9781461447313
Additional Edition:
Buchausg. u.d.T. ISBN 978-1-461-44731-3
Language:
English
DOI:
10.1007/978-1-4614-4732-0
URL:
Volltext
(lizenzpflichtig)
Bookmarklink
